The European Union’s drug regulator on Oct. 1 recommended updating the label for Johnson & Johnson’s COVID-19 vaccine with warnings for two more serious health conditions likely linked with the vaccine.
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) concluded that the use of the J&J vaccine is possibly linked with vein clotting and an immune condition that causes the immune system to attack blood platelets.
